13F Holdings
中文EN

IRWD IRONWOOD PHARMACEUTICALS INC

Pharmaceutical Preparations · Nasdaq · SEC CIK 1446847 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY18.1%
TTM net income YoY424.1%
TTM EPS YoY400.0%
Revenue 3-yr CAGR-2.5%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin62.9%
Net margin37.4%
FCF margin—
EBITDA margin63.2%

Returns

ROE—
ROA43.6%
ROIC (approx.)—
Asset turnover1.17x

Leverage & solvency

Liabilities / assets133.4%
Debt / equity—
Current ratio6.51x
Interest coverage8.28x

Cash quality & payout

Operating cash flow / net income1.37x
Accruals ratio-16.2%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q42025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q42024-12-31
Income statement
Revenue$133.04M$113.04M$106.51M$47.71M$122.06M$85.24M$41.14M$90.55M
R&D expense$28.35M$22.42M$21.94M$21.86M$22.47M$23.37M$27.43M$25.39M
SG&A expense$11.55M$11.31M$12.03M$19.29M$21.91M$16.80M$24.26M$33.59M
Operating income$93.13M$79.31M$72.57M$6.80M$75.48M$45.32M-$29.11M$31.49M
Interest expense$6.20M$7.20M$9.14M$7.89M$8.43M$8.36M$8.07M$8.91M
Pretax income$87.60M$73.73M$65.17M$455,000$68.02M$37.82M-$36.27M$24.00M
Income tax$27.76M$22.44M$24.40M$2.73M$27.94M$14.22M$1.11M$21.74M
Net income$59.84M$51.29M$40.77M-$2.28M$40.08M$23.60M-$37.39M$2.26M
EBITDA$93.59M$79.76M$73.02M$6.48M$75.96M$45.79M-$28.63M$31.16M
EPS (basic)0.360.310.25-0.010.250.15-0.23—
EPS (diluted)0.360.310.24-0.010.230.14-0.23—
Weighted avg. shares (diluted)168.18M167.18M166.69M—177.76M176.84M160.97M—
Balance sheet
Cash & equivalents$86.38M$79.13M$220.47M$215.46M$140.41M$92.85M$108.48M$88.56M
Receivables$132.72M$112.73M$105.84M$46.74M$120.37M$86.17M$39.77M$81.89M
Current assets$225.99M$199.20M$332.29M$274.18M$273.84M$191.75M$160.58M$182.37M
PP&E, net$2.66M$2.91M$3.17M$3.41M$3.67M$3.93M$4.26M$4.50M
Intangibles$1.43M$1.63M$1.84M$2.04M$2.25M$2.45M$2.66M$2.86M
Total assets$290.59M$285.13M$434.57M$396.90M$396.06M$342.95M$327.21M$350.91M
Current liabilities$34.73M$32.85M$236.31M$242.22M$242.50M$232.53M$48.10M$38.85M
Long-term debt————$199.51M$199.33M$199.16M$198.99M
Total debt————$199.51M$199.33M$199.16M$198.99M
Total liabilities$387.79M$446.97M$651.71M$658.74M$660.22M$651.11M$661.27M$652.24M
Shareholders' equity-$97.19M-$161.84M-$217.14M-$261.83M-$264.16M-$308.16M-$334.05M-$301.33M
Net debt————$59.10M$106.48M$90.68M$110.43M
Shares outstanding165.55M165.24M164.61M163.06M162.68M162.43M161.81M160.21M
Cash flow statement
Operating cash flow$67.40M$58.28M$5.12M$74.58M$47.58M-$15.07M$19.95M$15.21M
Capital expenditure———-$1,000$2,000$2,000$31,000$0
Free cash flow———$74.58M$47.58M-$15.07M$19.92M$15.21M
Investing cash flow———$1,000-$2,000-$2,000-$31,000$0
Financing cash flow-$60.00M——$122,000$0$88,000$6,000-$14.89M
Depreciation & amortization$459,000$457,000$443,000-$321,000$475,000$467,000$479,000-$326,000
Stock-based compensation$4.29M$3.24M$3.65M$3.82M$3.61M$4.52M$5.29M$4.57M

Free plan shows the latest 8 periods; Pro shows all 67 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.